https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30962 Wed 11 Apr 2018 10:28:39 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55012 Wed 03 Apr 2024 10:47:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51276 Tue 29 Aug 2023 15:47:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41245 Sat 30 Jul 2022 12:33:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23606 Sat 24 Mar 2018 07:13:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46604 400 g and/or >20-weeks' gestation, to women diagnosed with breast cancer in the first or second trimesters. Eighteen babies were exposed in utero to chemotherapy. Chemotherapy commenced at a median of 20 weeks gestation, for a mean duration of 10 weeks. Twelve exposed infants were born preterm with 11 by induced labour or pre-labour caesarean section. There were no perinatal deaths or congenital malformations. Our findings show that breast cancer diagnosed during mid-pregnancy is often treated with chemotherapy. Other than induced preterm births, there were no serious adverse perinatal outcomes.]]> Mon 28 Nov 2022 08:30:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39719 Fri 17 Jun 2022 17:31:03 AEST ]]>